محدّث
WHO updated recommendations on HIV clinical management: recommendations for a public health approach
World Health Organization
الأمراض المعدية 2025قاعدة المعارف الطبية
التوصيات السريرية
اطّلع على التوصيات الرسمية ووثائق التوافق والتحديثات المنشورة من قِبل الجمعيات العلمية والسلطات الصحية.
مصادر رسمية وموثوقةالجمعيات العلمية والسلطات الصحية
معلومات محدّثةرصد علمي مستمر
وصول مجاني للمهنيينفي خدمة المجتمع الطبي
تطبيق ASEM
إرشادات سريرية أينما كنت
استكشف التوصيات الطبية الرسمية والإرشادات السريرية في تطبيق ASEM.
احصل على تطبيق ASEMمنشورات وتحديثات مهمة
عرض المنشورات الحديثة
محدّث
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
European Society of Cardiology
أمراض القلب 2025
النشر الرسمي
WHO guidelines on the integrated management of obesity in adolescents
World Health Organization
طب الأطفال 2026جميع التوصيات (524 نتائج)
عوامل التصفية
Archived 41: Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada [2022-06-29]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 41: Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program i...
Archived 42: Summary of NACI statement of July 14, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 42: Summary of NACI statement of July 14, 2022: Recommendations on the use of Moderna Spikevax COV...
Archived 42: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age [2022-07-14]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 42: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 year...
Archived 43: Summary of NACI statement of August 19, 2022: Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 43: Summary of NACI statement of August 19, 2022: Recommendations on the use of a first booster do...
Archived 43: Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age [2022-08-19]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 43: Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vacci...
Archived 44: Summary of NACI statement: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 44: Summary of NACI statement: Updated guidance on COVID-19 vaccines for individuals who are pregn...
Archived 44: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding [2022-09-09]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 44: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding [2022-...
Archived 45: Summary of NACI statement of October 7, 2022: Updated guidance on COVID-19 vaccine booster doses in Canada
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 45: Summary of NACI statement of October 7, 2022: Updated guidance on COVID-19 vaccine booster dos...
Archived 45: Updated guidance on COVID-19 vaccine booster doses in Canada [2022-10-07]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 45: Updated guidance on COVID-19 vaccine booster doses in Canada [2022-10-07]”. Updated guidance o...
Archived 46: Summary of NACI statement of October 21, 2022: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 46: Summary of NACI statement of October 21, 2022: Recommendations on the use of Pfizer-BioNTech C...